News & Views |
Featured
-
-
-
News & Views |
Forcing an enemy into the open
A series of highly active, simplified analogues of the natural product bryostatin have been prepared. They offer an improved approach for the activation of latent HIV that could, in combination with current state-of-the-art antiretroviral therapy, offer hope for eventual eradication of the infection.
- Christian Melander
- & David M. Margolis
-
Article |
Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro
Simplified bryostatin analogues are shown to potently induce latent HIV expression in vitro. These analogues display comparable or better potency when compared with bryostatin. Moreover, they are up to 1,000-fold more potent in inducing latent HIV expression than prostratin, the current lead preclinical candidate.
- Brian A. DeChristopher
- , Brian A. Loy
- & Paul A. Wender
-
News & Views |
A light touch to a deadly problem
Flow chemistry has grown in stature as a technique with the potential to deliver synthetic complexity with assembly-line-like efficiency. Application of flow technology to the front-line antimalarial drug artemisinin promises to revolutionalize treatment.
- Kevin Booker-Milburn
-
Blogroll |
Blogroll: Arnie and artemisinin
-
Article |
Synthesis of 3-O-sulfonated heparan sulfate octasaccharides that inhibit the herpes simplex virus type 1 host–cell interaction
Oligosaccharides displayed at cell surfaces have important biological functions — such as controlling the entry of viruses — but a full understanding of this behaviour requires the synthesis of such compounds, which remains challenging. Here, two synthetic octasaccharides were shown to have remarkably similar inhibition of herpes simplex virus type 1 infection of cell cultures to the natural oligosaccharide identified in enzymatic studies.
- Yu-Peng Hu
- , Shu-Yi Lin
- & Shang-Cheng Hung